NovaBay Pharmaceuticals, Inc. — Director's Dealing 2021

Nov 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NovaBay Pharmaceuticals, Inc. (NBY)
CIK: 0001389545
Period of Report: 2021-11-22

Reporting Person: Kunin Audrey (Chief Product Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-22	Common Stock	P	25000	$0.46	Acquired	25000	Indirect
2021-11-23	Common Stock	P	66133	$0.4592	Acquired	91133	Indirect

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $0.4545 to $0.4610. The price reported above reflected the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: By The Audrey G. Kunin Trust in which the reporting person serves as the trustee and has investment control.